Neuromuscular blocking agents are not used routinely in patients undergoing mechanical ventilation because of the risk of prolonged neuromuscular weakness and the need for continuous heavy sedation; however, one study did show reduced mortality at 90 days in patients with early, severe ARDS who received 48 hours of neuromuscular blockade (1).